Anti‐angiogenic and anti‐tumor effects of TAK‐593, a potent and selective inhibitor of vascular endothelial growth factor and platelet‐derived growth factor receptor tyrosine kinase

Abstract

We recently reported that TAK-593, a novel imidazo [1,2-b]pyridazine derivative, is a highly potent and selective inhibitor of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor tyrosine kinase families. Moreover, TAK-593 exhibits a uniquely long-acting inhibitory profile towards VEGF receptor 2 (VEGFR2) and PDGF receptor b (PDGFRb).In this study, we demonstrated that TAK-593 potently inhibits VEGF-and PDGF-stimulated cellular phosphorylation and proliferation of human umbilical vein endothelial cells and human coronary artery smooth muscle cells. TAK-593 also potently inhibits VEGF-induced tube formation of endothelial cells co-cultured with fibroblasts. Oral administration of TAK-593 exhibited strong anti-tumor effects against various human cancer xenografts along with good tolerability despite a low level of plasma exposure. Even after the blood and tissue concentrations of TAK-593 decreased below the detectable limit, a pharmacodynamic marker (phospho VEGFR2) was almost completely suppressed, indicating that its long duration of enzyme inhibition might contribute to the potent activity of TAK-593. Immunohistochemical staining indicated that TAK-593 showed anti-proliferative and pro-apoptotic effects on tumors along with a decrease of vessel density and inhibition of pericyte recruitment to microvessels in vivo. Furthermore, dynamic contrast-enhanced magnetic resonance imaging revealed that TAK-593 reduced tumor vessel permeability prior to the onset of anti-tumor activity. In conclusion, TAK-593 is an extremely potent VEGFR/PDGFR kinase inhibitor whose potent anti-angiogenic activity suggests therapeutic potential for the treatment of solid tumors. (Cancer Sci 2013; 104: 486-494)

Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2

“…Angiogenesis is critical for tumor growth and progression, because it forms a network of blood vessels which penetrate into cancer growth to supply nutrients and oxygen and to remove metabolic waste from the tumor. Therefore, tumor growth and metastasis are highly dependent upon the angiogenic process 1 , implying that anti-angiogenic drugs may be important in the cancer therapy 2 . Indeed, anti-angiogenic agents have been proven to inhibit the growth of a wide variety of solid tumors in animal models by reducing tumor blood supply 3 .…”

Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer

“…Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis that induces the formation of novel blood vessels, and growth and metastasis of cancers. Several researches have revealed that VEGF plays an important role in promoting endothelial cell proliferation and migration, and induces a direct effect on cancer proliferation and invasiveness (Awazu et al 2013;Hu et al 2013;Sun et al 2014). It has been reported that TBC domain containing proteins also participate in cancer proliferation and angiogenesis via VEGF (Kim et al 2003;Ji et al 2004).…”

MicroRNA-126 affects ovarian cancer cell differentiation and invasion by modulating expression of vascular endothelial growth factor

“…The growth and spread of tumors depends on the formation of an adequate vascular support and amoeboid mode of tumor cell invasion (9). Furthermore, several studies have indicated that VEGF serves a role in promoting endothelial cell proliferation and migration, and induces a direct effect on cell proliferation and invasiveness (3,10,11). Previous studies have indicated that suppressing the expression or activity VEGF in ovarian cancer cells may represent a potential anticancer therapy (12)(13)(14).…”